Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California.  In addition, the company announced that it has commenced enrollment of patients with type 2 diabetes in its Phase 2b clinical trial of LX4211.

Data from the mechanistic study demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.

The Phase 2b trial is a randomized, double-blind, placebo controlled study of LX4211 in approximately 285 adult patients (18-75 years) with type 2 diabetes who are not adequately controlled on metformin monotherapy.  Patients will be administered LX4211 in combination with standard metformin therapy over 12 weeks.  Doses will include 75 mg once daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily or placebo.  The primary endpoint of the study is the change from baseline in HbA1c at Week 12.  Secondary endpoints will include percentage of patients achieving HbA1c < 7%, and changes in fasting plasma glucose, 3-hour glucose tolerance test, weight, blood pressure, and triglycerides.  The study will be conducted at ap
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... addition of the "The Corporate Reputation of ... Global Edition " report to their offering. ... Patient Perspective, is now in its fourth edition. ... published early 2015). For each annual Corporate Reputation ...
(Date:4/16/2015)... WASHINGTON , April 16, 2015 Vanda ... company focused on the development and commercialization of products ... announced it will release results for the first quarter ... market closes. The Company will host ... May 6, 2015, during which Vanda management will discuss ...
(Date:4/16/2015)... Calif. , April 16, 2015  Amgen (NASDAQ: ... its first quarter financial results on Tuesday, April 21, ... The announcement will be followed by a conference call ... in the call from Amgen will be Robert ... other members of Amgen,s senior management team. ...
Breaking Medicine Technology:The Corporate Reputation of Pharma - The Global Patient Perspective in 2014 2Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2Amgen Announces Webcast Of 2015 First Quarter Financial Results 2
... the public about the,need and benefits of angioplasty, ... onslaught of,anti-stent news reports over the past few ... work and its use should,decrease. Confused by the ... the benefits of stenting. , "Doctor and patient ...
... /PRNewswire-FirstCall/ -- Vanda,Pharmaceuticals Inc. announced today that Dr. ... and Research Center in Detroit, MI,will deliver an ... for VEC-162, Vanda's balanced melatonin (MT1/MT2),receptor agonist, at ... Professional Sleep Societies, (APSS). , The Vanda presentation ...
Cached Medicine Technology:To Stent or Not: Is That the Question? 2Vanda Pharmaceuticals To Present Data on VEC-162 at SLEEP 2007, the,Annual Meeting of the Associated Professional Sleep Societies 2
(Date:4/18/2015)... Aureus Medical Group (web: aureusmedical.com), ... therapy jobs, has announced that it will participate ... Therapy Association Annual Conference to be held May ... SC. , The SCAPTA Annual Conference offers ... and services. , Representatives from Aureus Medical’s ...
(Date:4/18/2015)... FL (PRWEB) April 18, 2015 PHOENIX, ... Hillsborough County, along with 11 other secure destruction professionals ... Secure Destruction Specialists (CSDS). He will now display “CSDS” ... exams were offered before the National Association of Information ... Illinois and another Grapevine, Texas. Of the 20 people ...
(Date:4/17/2015)... Heritage Woods of McLeansboro, a Gardant affordable ... Celebration on April 20 with a day full of ... and soul. , The community, which is located at ... of all incomes, including those on Medicaid, who need ... Week is observed every April and highlights the communities ...
(Date:4/17/2015)... Rosetta Radiology is proud to now offer ... of diagnostic imaging services. This solidifies them as a ... East Side of Manhattan. , The new imaging equipment ... of PET-CT, combined with Rosetta’s state of the art ... with patients through several stages of the cancer care ...
(Date:4/17/2015)... Riviera Magazine has featured board ... the Gallery of Cosmetic Surgery in Newport Beach, California ... The publication focused on his expertise in the lower ... eyelid surgery, laser resurfacing and rhinoplasty. , Dr. Sadati’s ... resulted in thousands of satisfied patients across the globe. ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the South Carolina Physical Therapy Association Annual Conference 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 2Health News:Heritage Woods of McLeansboro Affordable Assisted Living to Celebrate Supportive Living Week 3Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 2Health News:Orange County Facial Plastic Surgeon Featured in Premier Magazine Focused on Beauty 3
... nongovernmental organizations has published a report proposing a set ... asthma clinical research. Asthma Outcomes in Clinical Research: Report ... supplement to the March 2012 issue of the ... a meeting organized by the National Institutes of Health, ...
... March 2 (HealthDay News) -- Women become less likely to ... year of college, new research finds. Declining condom use ... worse grades and who came from poorer backgrounds. "We ... pregnancies and sexually transmitted diseases, yet there has been a ...
... memory is observed in people who consume drugs containing ... team led by Giovanni Marsicano (Inserm Research Unit 862) ... has recently identified the mechanism by which these substances ... first time that the adverse effect of cannabinoids on ...
... Survivors of cancer in childhood have a higher risk ... reached by Magdalena Balcerek and her co-authors in a ... Arztebl Int 2012; 109[7] 126-31). , In a nationwide ... childhood and adolescence, the authors collected data from former ...
... Reinberg HealthDay Reporter , THURSDAY, March 1 (HealthDay ... for cervical cancer are more likely to survive if they ... suggests. Compared to women whose cervical cancer is detected ... increased their cure rate from 66 percent to more than ...
... the 27,000 plus people around the world who donate a ... donors for 10 years found that they were at no ... Led by Dr. Amit Garg, a researcher ... Sciences Centre, the results provide important safety reassurances to donors, ...
Cached Medicine News:Health News:Standardized outcome measures proposed for asthma clinical research 2Health News:College Women's Condom Use Falls During Freshman Year 2Health News:How does cannabis affect working memory? 2Health News:How does cannabis affect working memory? 3Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 2Health News:Regular Pap Smear Boosts Cervical Cancer Survival: Study 3Health News:First study of its kind finds no increased risk of heart disease for kidney donors 2
The rotating stage assembly is designed to give the researcher maximum flexibility in the mounting of specimens. It can be turned to any horizontal and vertical angle via a ball joint mounting arran...
The glass knife adapter allows for the use of glass knives or ralph knives on the Vibratome. The adapter can be installed in place of the standard razor blade mounting device....
Inquire...
Inquire...
Medicine Products: